Warfarin Pharmacology, Clinical Management, and Evaluation of Hemorrhagic Risk for the Elderly

Laurie G. Jacobs

Research output: Contribution to journalArticle

46 Citations (Scopus)

Abstract

Warfarin, a vitamin K antagonist, is currently the most extensively used oral anticoagulant world-wide. It is prescribed for a variety of indications and has undergone extensive clinical study. Still, despite wide usage and considerable accumulated data from clinical trials demonstrating efficacy for a variety of thrombotic and thromboembolic conditions, warfarin is underutilized because its management is complex for both patients and physicians. However, despite these limitations, warfarin can be managed with relative safety, even in an elderly population.

Original languageEnglish (US)
Pages (from-to)157-167
Number of pages11
JournalCardiology Clinics
Volume26
Issue number2
DOIs
StatePublished - May 2008

Fingerprint

Clinical Pharmacology
Warfarin
Vitamin K
Anticoagulants
Clinical Trials
Physicians
Safety
Population

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Warfarin Pharmacology, Clinical Management, and Evaluation of Hemorrhagic Risk for the Elderly. / Jacobs, Laurie G.

In: Cardiology Clinics, Vol. 26, No. 2, 05.2008, p. 157-167.

Research output: Contribution to journalArticle

@article{d75eed4278044bc69160260bd631a6fd,
title = "Warfarin Pharmacology, Clinical Management, and Evaluation of Hemorrhagic Risk for the Elderly",
abstract = "Warfarin, a vitamin K antagonist, is currently the most extensively used oral anticoagulant world-wide. It is prescribed for a variety of indications and has undergone extensive clinical study. Still, despite wide usage and considerable accumulated data from clinical trials demonstrating efficacy for a variety of thrombotic and thromboembolic conditions, warfarin is underutilized because its management is complex for both patients and physicians. However, despite these limitations, warfarin can be managed with relative safety, even in an elderly population.",
author = "Jacobs, {Laurie G.}",
year = "2008",
month = "5",
doi = "10.1016/j.ccl.2007.12.010",
language = "English (US)",
volume = "26",
pages = "157--167",
journal = "Cardiology Clinics",
issn = "0733-8651",
publisher = "W.B. Saunders Ltd",
number = "2",

}

TY - JOUR

T1 - Warfarin Pharmacology, Clinical Management, and Evaluation of Hemorrhagic Risk for the Elderly

AU - Jacobs, Laurie G.

PY - 2008/5

Y1 - 2008/5

N2 - Warfarin, a vitamin K antagonist, is currently the most extensively used oral anticoagulant world-wide. It is prescribed for a variety of indications and has undergone extensive clinical study. Still, despite wide usage and considerable accumulated data from clinical trials demonstrating efficacy for a variety of thrombotic and thromboembolic conditions, warfarin is underutilized because its management is complex for both patients and physicians. However, despite these limitations, warfarin can be managed with relative safety, even in an elderly population.

AB - Warfarin, a vitamin K antagonist, is currently the most extensively used oral anticoagulant world-wide. It is prescribed for a variety of indications and has undergone extensive clinical study. Still, despite wide usage and considerable accumulated data from clinical trials demonstrating efficacy for a variety of thrombotic and thromboembolic conditions, warfarin is underutilized because its management is complex for both patients and physicians. However, despite these limitations, warfarin can be managed with relative safety, even in an elderly population.

UR - http://www.scopus.com/inward/record.url?scp=41749123452&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=41749123452&partnerID=8YFLogxK

U2 - 10.1016/j.ccl.2007.12.010

DO - 10.1016/j.ccl.2007.12.010

M3 - Article

C2 - 18406992

AN - SCOPUS:41749123452

VL - 26

SP - 157

EP - 167

JO - Cardiology Clinics

JF - Cardiology Clinics

SN - 0733-8651

IS - 2

ER -